title: Original version Date: 2014
text: |
  Original version Date: 2014
  |
  bet | 408/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Original version Date: 2014
  |
  Author: AK, JD
  |
  Current Version number: 2.0
  |
  Current Version Date: 24/12/2020
  |
  Risk Rating: Medium
  |
  Due for Review: 24/12/2025
  |
  Approval by: DTC
  |
  Approval Date: TBA
  |
  Omeprazole |
  Revision Date :19/07/2018
  |
  Approved: TC, KOH
  |
  Alert
  |
  Short- and long-term safety data in infants are limited. There have been several safety concerns with long-term usage in adults.
  The bioavailability of the in-house pharmacy suspension made from the contents of the capsule may be less (up to 50% less) than that of the capsule itself. Dose may need to be adjusted if no clinical response.
  |
  Indication
  |
  Treatment of gastroesophageal reflux disease (GORD).
  Prophylaxis in congenital tracheoesophageal fistula and oesophageal atresia (role unclear).
  |
  Action
  |
  Omeprazole is a proton pump inhibitor (PPI).
  |
  Drug Type
  |
  Proton Pump Inhibitor.
  |
  Trade Name
  |
  APO-Omeprazole Capsules (Apotex) 20 mg
  Omeprazole Sandoz IV Powder for injection (Sandoz]) 40 mg.
  |
  Presentation
  |
  20 mg/capsule; 10 mg tablets; 20 mg tablets.
  Oral suspension of 2 mg/mL prepared in pharmacy.
  Omeprazole Sandoz IV Powder for injection 40 mg.
  |
  Dosage / Interval
  |
  PO: 0.5–1.5 mg/kg/dose daily
  IV: 0.5 mg/kg/dose daily
  |
  Maximum daily dose
  |
  1.5 mg/kg/dose
  |
  Route
  |
  PO, IV
  |
  Preparation/Dilution
  |
  PO: In-house pharmacy can prepare a 2 mg/mL suspension using these capsules as follows: Disperse 100 mg omeprazole in 50 mL of 8.4% sodium bicarbonate solution.
  1 mL of omeprazole suspension contains 2 mg omeprazole, 1 mmol sodium and 1 mmol bicarbonate.
  IV: Add 10 mL of sodium chloride 0.9% to 40 mg powder for reconstitution to make a concentration of 4 mg/mL. Draw up 1 mL (4 mg) and add 9 mL of sodium chloride 0.9% to make a final volume of 10 mL with a concentration of 0.4 mg/mL.
  |
  Administration
  |
  PO: Administer prior to meals.
  IV: Infuse over 30 minutes.
  |
  Monitoring
  |
  Serum magnesium in patients on prolonged therapy or who use digoxin or drugs that may cause hypomagnesaemia (e.g. diuretics) concomitantly.20-21
  Serum vitamin B12 — every 1 to 2 years in patients on prolonged therapy.20-21
  |
  |
  |
  | |